Cantor Fitzgerald Reiterates Overweight on Longboard Pharmaceuticals, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Alethia Young has reiterated an Overweight rating on Longboard Pharmaceuticals and maintained a $16 price target.
July 06, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Longboard Pharmaceuticals, maintaining a $16 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Longboard Pharmaceuticals. The maintained price target of $16 suggests that the analyst believes the stock is undervalued at current prices, which could lead to upward pressure on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100